Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Angeliki Paleta"'
Autor:
Ioanna Sakellari, Maria Karypidou, Ioannis Batsis, Angeliki Paleta, Panagiota Zerva, Konstantina Kotta, Tasoula Touloumenidou, Apostolia Papalexandri, Evangelia Stalika, Despina Mallouri, Anastasia Hadzidimitriou, Ioannis Kotsianidis, Dimitris Margaritis, Kostas Stamatopoulos, Achilles Anagnostopoulos
Publikováno v:
Leukemialymphoma. 60(7)
Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene re
Autor:
Ioanna Sakellari, Apostolia Papalexandri, Eirini Baldoumi, Christos Demosthenous, Despina Mallouri, Angeliki Paleta, Achilles Anagnostopoulos, Evangelia Yannaki, Fotini S. Kika, Panagiota Zerva, Eleni Gavriilaki, Natasa Konstantinou, Tasoula Touloumenidou, Michalis Iskas, Ioannis Batsis, Anna Vardi
Publikováno v:
Blood. 136:31-31
Introduction: Reactivation of Epstein-Barr virus (EBV) is common in allogeneic hematopoietic cell transplantation (HCT). EBV infection leads to post-transplantation lymphoproliferative disease (PTLD), a life-threatening complication in this setting.
Autor:
Damianos Sotiropoulos, Maria Papathanasiou, Evaggelia Yannaki, Ioanna Sakellari, Ioannis Batsis, Aliki Tsompanakou, Vasiliki Douka, Angeliki Paleta, Maria Karypidou, Apostolia Papalexandri, Despina Mallouri, Tasoula Touloumenidou, Achilles Anagnostopoulos, Konstantina Kotta
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:S302
Autor:
Panagiotis Baliakas, Damianos Sotiropoulos, Eva Koravou, Angeliki Paleta, Michalis Iskas, Kostas Stamatopoulos, Fotis Iordanidis, Achilles Anagnostopoulos, Vassiliki Douka, Anta Cheva, Tasoula Touloumenidou, Leonidas Sakkas
Publikováno v:
Blood. 122:5268-5268
The JAK2 V617F mutation is of high diagnostic value in the evaluation of myeloproliferative neoplasms (MPN) as it helps to document clonality; in addition, it may also predict for response to hydroxyurea treatment. According to recent studies, the pr
Autor:
Christos Smias, Evangelia Stalika, Georgia Voutiadou, Angeliki Paleta, Apostolia Papalexandri, Tasoula Touloumenidou, Achilles Anagnostopoulos, Ioannis Batsis, Ioanna Sakellari, Ioannis Zorbas, Chryssa Apostolou
Publikováno v:
Blood. 116:1297-1297
Abstract 1297 Relapse remains the most common cause of treatment failure in patients with hematological malignancies undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Prediction of relapse by detection of minimal residual disease (